On Feb. 19, 2025, Alcon announced the full U.S. commercial availability of Voyager^™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients.

Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with manual SLT.

Glaucoma is a progressive disease that impacts millions of people around the world. In the U.S. alone, the number of glaucoma patients is expected to grow from 5 million to 6.3 million by 2050. Glaucoma is the leading cause of irreversible blindness globally, with many unaware that they have glaucoma until the disease has progressed to vision loss. Due to its progressive nature, early intervention and a variety of treatment options—from drops to surgical intervention—is critical to preserve sight.

Voyager DSLT is controlled through an intuitive touchscreen, taking the slit lamp and manual gonio lens aiming out of the equation, and reduces the specialized training required with manual SLT. Voyager DSLT offers precise delivery, powered by SureTrac™ eye-tracking technology, to accurately and safely deliver laser pulses through the limbus to the trabecular meshwork, stimulating the eye’s natural healing response to improve aqueous outflow.

Voyager DSLT is indicated to perform SLT and is currently available in select markets in the E.U., the U.K. and now the U.S.